Literature DB >> 11596100

Human immune response to Puumala virus glycoproteins and nucleocapsid protein expressed in mammalian cells.

H Kallio-Kokko1, R Leveelahti, M Brummer-Korvenkontio, A Vaheri, O Vapalahti.   

Abstract

Puumala hantavirus (PUUV) glycoproteins G1 and G2 and nucleocapsid protein (N) were expressed in BHK-21 cells by transfection of a plasmid producing a recombinant alphavirus replicon. Coexpression of G1 and G2 from separate constructs seemed to be important for the optimal folding of the glycoproteins, as evaluated by a panel of MAbs detecting conformational epitopes. To evaluate the human antibody response against recombinant G1, G2 and N, several panels of sera were tested by immunofluorescence assay (IFA). Also human sera showed the best reactivity towards G1 and G2 coexpressed from separate transcripts (G1 + G2). Notably, only 2% of the acute sera (total number = 133) contained IgG antibodies against G1 + G2, whereas of old-immunity sera (total number = 100) 87% were G1 + G2 positive. Analysis of a panel of serial patient sera showed that as the immunity matured, IgG antibodies against the recombinant glycoproteins appeared and the titers increased in the course of time, while antibodies against the recombinant N were present already in the acute phase in high titers. The granular fluorescence pattern in PUUV IgG-IFA, associated with the acute phase of immunity, was linked to the presence of antibodies against N, whereas the diffuse fluorescence pattern associated with old-immunity, was linked to the development of antibodies against G1 + G2. The granular fluorescence pattern in PUUV IgG-IFA had a predictive value of 100% for acute PUUV infection. Weak cross-reaction with PUUV glycoproteins was observed in 36% of old-immunity DOBV-specific human sera. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11596100

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  20 in total

1.  Hantavirus and arenavirus antibody prevalence in rodents and humans in Trentino, Northern Italy.

Authors:  H Kallio-Kokko; J Laakkonen; A Rizzoli; V Tagliapietra; I Cattadori; S E Perkins; P J Hudson; A Cristofolini; W Versini; O Vapalahti; A Vaheri; H Henttonen
Journal:  Epidemiol Infect       Date:  2005-12-22       Impact factor: 2.451

2.  Competitive Homogeneous Immunoassay for Rapid Serodiagnosis of Hantavirus Disease.

Authors:  Satu Hepojoki; Juuso Rusanen; Jussi Hepojoki; Visa Nurmi; Antti Vaheri; Åke Lundkvist; Klaus Hedman; Olli Vapalahti
Journal:  J Clin Microbiol       Date:  2015-05-13       Impact factor: 5.948

3.  Development of novel immunoglobulin G (IgG), IgA, and IgM enzyme immunoassays based on recombinant Puumala and Dobrava hantavirus nucleocapsid proteins.

Authors:  Helga Meisel; Anne Wolbert; Ausra Razanskiene; Andreas Marg; Andris Kazaks; Kestutis Sasnauskas; Georg Pauli; Rainer Ulrich; Detlev H Krüger
Journal:  Clin Vaccine Immunol       Date:  2006-10-04

Review 4.  A global perspective on hantavirus ecology, epidemiology, and disease.

Authors:  Colleen B Jonsson; Luiz Tadeu Moraes Figueiredo; Olli Vapalahti
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

5.  Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine.

Authors:  R L Brocato; M J Josleyn; V Wahl-Jensen; C S Schmaljohn; J W Hooper
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

6.  Rapid homogeneous immunoassay based on time-resolved Förster resonance energy transfer for serodiagnosis of acute hantavirus infection.

Authors:  Satu Hepojoki; Jussi Hepojoki; Klaus Hedman; Olli Vapalahti; Antti Vaheri
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

Review 7.  Human pathogenic hantaviruses and prevention of infection.

Authors:  Detlev H Krüger; Günther Schönrich; Boris Klempa
Journal:  Hum Vaccin       Date:  2011-06-01

8.  Hantavirus entry: Perspectives and recent advances.

Authors:  Eva Mittler; Maria Eugenia Dieterle; Lara M Kleinfelter; Megan M Slough; Kartik Chandran; Rohit K Jangra
Journal:  Adv Virus Res       Date:  2019-08-07       Impact factor: 9.937

9.  Indirect immunofluorescence assay for the simultaneous detection of antibodies against clinically important old and new world hantaviruses.

Authors:  Sabine Lederer; Erik Lattwein; Merle Hanke; Karen Sonnenberg; Winfried Stoecker; Åke Lundkvist; Antti Vaheri; Olli Vapalahti; Paul K S Chan; Heinz Feldmann; Daryl Dick; Jonas Schmidt-Chanasit; Paula Padula; Pablo A Vial; Raluca Panculescu-Gatej; Cornelia Ceianu; Paul Heyman; Tatjana Avšič-Županc; Matthias Niedrig
Journal:  PLoS Negl Trop Dis       Date:  2013-04-04

Review 10.  Immune response during hantavirus diseases: implications for immunotherapies and vaccine design.

Authors:  Farides Saavedra; Fabián E Díaz; Angello Retamal-Díaz; Camila Covián; Pablo A González; Alexis M Kalergis
Journal:  Immunology       Date:  2021-03-18       Impact factor: 7.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.